These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 39064697)

  • 1. The Effect of Mobile Lifestyle Intervention Combined with High-Protein Meal Replacement on Liver Function in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Pilot Randomized Controlled Trial.
    Cho E; Kim S; Kim S; Kim JY; Kim HJ; Go Y; Lee YJ; Lee H; Gil S; Yoon SK; Chu K
    Nutrients; 2024 Jul; 16(14):. PubMed ID: 39064697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C--a randomized trial.
    Rusu E; Jinga M; Enache G; Rusu F; Dragomir AD; Ancuta I; Draguţ R; Parpala C; Nan R; Sima I; Ateia S; Stoica V; Cheţa DM; Radulian G
    Nutr J; 2013 Aug; 12():119. PubMed ID: 23941362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of smartphone-assisted lifestyle intervention in MASLD patients: a randomized controlled trial.
    Kaewdech A; Assawasuwannakit S; Churuangsuk C; Chamroonkul N; Sripongpun P
    Sci Rep; 2024 Jun; 14(1):13961. PubMed ID: 38886203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender Differences in Liver Steatosis and Fibrosis in Overweight and Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease before and after 8 Weeks of Very Low-Calorie Ketogenic Diet.
    Rinaldi R; De Nucci S; Donghia R; Donvito R; Cerabino N; Di Chito M; Penza A; Mongelli FP; Shahini E; Zappimbulso M; Pesole PL; Coletta S; Triggiani V; Cozzolongo R; Giannelli G; De Pergola G
    Nutrients; 2024 May; 16(10):. PubMed ID: 38794646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mobile App-Based Lifestyle Coaching Intervention for Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial.
    Kwon OY; Lee MK; Lee HW; Kim H; Lee JS; Jang Y
    J Med Internet Res; 2024 Feb; 26():e49839. PubMed ID: 38358794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of elevated liver enzymes in blood donors: associations with male gender and central adiposity.
    Papatheodoridis GV; Goulis J; Christodoulou D; Manolakopoulos S; Raptopoulou M; Andrioti E; Alexandropoulos N; Savvidou S; Papachristou A; Zervou E; Seferiadis K; Kousidou P; Vogiatzakis E; Tsianos E
    Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):281-7. PubMed ID: 17353691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
    Cusi K; Sattar N; García-Pérez LE; Pavo I; Yu M; Robertson KE; Karanikas CA; Haupt A
    Diabet Med; 2018 Oct; 35(10):1434-1439. PubMed ID: 29869810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
    Katsagoni CN; Papatheodoridis GV; Ioannidou P; Deutsch M; Alexopoulou A; Papadopoulos N; Papageorgiou MV; Fragopoulou E; Kontogianni MD
    Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of 1-year pemafibrate treatment on steatotic liver disease: the influence of alcohol consumption.
    Iwasa M; Sugimoto R; Eguchi A; Tamai Y; Shigefuku R; Fujiwara N; Tanaka H; Kobayashi Y; Ikoma J; Kaito M; Nakagawa H
    Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):793-801. PubMed ID: 38526942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial.
    Aller R; De Luis DA; Izaola O; Conde R; Gonzalez Sagrado M; Primo D; De La Fuente B; Gonzalez J
    Eur Rev Med Pharmacol Sci; 2011 Sep; 15(9):1090-5. PubMed ID: 22013734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lifestyle Intervention Enabled by Mobile Technology on Weight Loss in Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial.
    Lim SL; Johal J; Ong KW; Han CY; Chan YH; Lee YM; Loo WM
    JMIR Mhealth Uhealth; 2020 Apr; 8(4):e14802. PubMed ID: 32281943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors.
    St George A; Bauman A; Johnston A; Farrell G; Chey T; George J
    J Gastroenterol Hepatol; 2009 Mar; 24(3):399-407. PubMed ID: 19067776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Obesity and Metabolic Health Status on Metabolic-Associated Steatotic Liver Disease among Renal Transplant Recipients Using Hepatic Steatosis Index.
    Lin IH; Yu YP; Duong TV; Nien SW; Tseng IH; Wu YM; Chiang YJ; Chiang CY; Chiu CH; Wang MH; Yang NC; Wu TH; Wong TC
    Nutrients; 2024 Oct; 16(19):. PubMed ID: 39408311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin resistance and metabolic syndrome in patients with NAFLD but without diabetes: effect of a 6 month regime intervention.
    Cankurtaran M; Tayfur O; Yavuz BB; Geyik S; Akhan O; Arslan S
    Acta Gastroenterol Belg; 2007; 70(3):253-9. PubMed ID: 18074733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: Results from the Fatty Liver in Obesity trial.
    Mogna-Peláez P; Riezu-Boj JI; Milagro FI; Herrero JI; Elorz M; Benito-Boillos A; Tobaruela-Resola AL; Tur JA; Martínez JA; Abete I; Zulet MA
    Clin Nutr; 2024 Jul; 43(7):1770-1781. PubMed ID: 38861890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and predictors of elevated liver enzyme levels in Mexico: The Mexican National Health and Nutrition Survey, 2016.
    Denova-Gutiérrez E; Lara-Castor L; Hernández-Alcaraz C; Hernández-Ávila M; Aguilar-Salinas C; Kershenobich D; Barquera S
    Ann Hepatol; 2021 Dec; 26():100562. PubMed ID: 34653686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating alanine transaminase (ALT) and γ-glutamyl transferase (GGT), but not fetuin-A, are associated with metabolic risk factors, at baseline and at two-year follow-up: the prospective Cyprus Metabolism Study.
    Liu X; Hamnvik OP; Chamberland JP; Petrou M; Gong H; Christophi CA; Christiani DC; Kales SN; Mantzoros CS
    Metabolism; 2014 Jun; 63(6):773-82. PubMed ID: 24726813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic dysfunction-associated steatotic liver disease is associated with worse time in ranges in type 1 diabetes.
    Aernouts C; Beldé SPW; Lambrechts J; Mertens J; Ledeganck KJ; Francque SM; De Block CEM
    Diabetes Obes Metab; 2024 Sep; 26(9):3781-3790. PubMed ID: 38924290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-sectional pilot study about the liver enzymes profile in type 2 diabetic patients from an Algerian west region: Wilaya of Mostaganem.
    Belkacemi L; Belalia M
    Diabetes Metab Syndr; 2016; 10(1 Suppl 1):S147-50. PubMed ID: 26711007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone augmentation in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials.
    Mohamed I; Gautam M; Abosheaishaa H; Hussain S; Kumar K; Kotak A; Baugh M; Qureshi R; Jaber F; Dahiya DS; Alba L; Duong N
    Eur J Gastroenterol Hepatol; 2024 Nov; 36(11):1259-1266. PubMed ID: 38973533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.